CN106692973A - 一种组合物及其用途、药物制剂 - Google Patents

一种组合物及其用途、药物制剂 Download PDF

Info

Publication number
CN106692973A
CN106692973A CN201610303976.5A CN201610303976A CN106692973A CN 106692973 A CN106692973 A CN 106692973A CN 201610303976 A CN201610303976 A CN 201610303976A CN 106692973 A CN106692973 A CN 106692973A
Authority
CN
China
Prior art keywords
acid
composition according
acceptable
diseases
liver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610303976.5A
Other languages
English (en)
Chinese (zh)
Inventor
刘利平
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Hightide Biopharmaceutical Ltd
Original Assignee
Shenzhen Hightide Biopharmaceutical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Hightide Biopharmaceutical Ltd filed Critical Shenzhen Hightide Biopharmaceutical Ltd
Priority to CN202310452983.1A priority Critical patent/CN116492339A/zh
Priority to CA3023648A priority patent/CA3023648C/en
Priority to JP2018559306A priority patent/JP2019518738A/ja
Priority to IL300237A priority patent/IL300237A/en
Priority to PCT/CN2016/105294 priority patent/WO2017193563A1/zh
Priority to AU2016406709A priority patent/AU2016406709C1/en
Priority to EP16901518.7A priority patent/EP3456328A4/en
Priority to KR1020187034961A priority patent/KR102892545B1/ko
Publication of CN106692973A publication Critical patent/CN106692973A/zh
Priority to IL262929A priority patent/IL262929B2/en
Priority to JP2021180724A priority patent/JP7448511B2/ja
Priority to AU2023200123A priority patent/AU2023200123B2/en
Priority to JP2023189115A priority patent/JP7668859B2/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201610303976.5A 2015-11-13 2016-05-10 一种组合物及其用途、药物制剂 Pending CN106692973A (zh)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CN202310452983.1A CN116492339A (zh) 2015-11-13 2016-05-10 一种组合物及其用途、药物制剂
AU2016406709A AU2016406709C1 (en) 2016-05-10 2016-11-10 Composition, and application and pharmaceutical preparation thereof
JP2018559306A JP2019518738A (ja) 2015-11-13 2016-11-10 組成物、ならびにその適用および薬学的調製の方法
IL300237A IL300237A (en) 2015-11-13 2016-11-10 Preparations for treatment, methods for their preparation and their uses
PCT/CN2016/105294 WO2017193563A1 (zh) 2015-11-13 2016-11-10 一种组合物及其用途、药物制剂
CA3023648A CA3023648C (en) 2016-05-10 2016-11-10 Pharmaceutical composition of berberine with epa and dha
EP16901518.7A EP3456328A4 (en) 2016-05-10 2016-11-10 COMPOSITION AND USE AND PHARMACEUTICAL PREPARATION THEREOF
KR1020187034961A KR102892545B1 (ko) 2015-11-13 2016-11-10 조성물, 그 용도 및 약학적 제제
IL262929A IL262929B2 (en) 2015-11-13 2018-11-11 Preparations for treatment, methods for their preparation and their uses
JP2021180724A JP7448511B2 (ja) 2015-11-13 2021-11-05 組成物、ならびにその適用および薬学的調製の方法
AU2023200123A AU2023200123B2 (en) 2016-05-10 2023-01-11 Composition, and application and pharmaceutical preparation thereof
JP2023189115A JP7668859B2 (ja) 2015-11-13 2023-11-06 組成物、ならびにその適用および薬学的調製の方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562254739P 2015-11-13 2015-11-13
US62/254,739 2015-11-13

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310452983.1A Division CN116492339A (zh) 2015-11-13 2016-05-10 一种组合物及其用途、药物制剂

Publications (1)

Publication Number Publication Date
CN106692973A true CN106692973A (zh) 2017-05-24

Family

ID=58939703

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201610303976.5A Pending CN106692973A (zh) 2015-11-13 2016-05-10 一种组合物及其用途、药物制剂
CN202310452983.1A Pending CN116492339A (zh) 2015-11-13 2016-05-10 一种组合物及其用途、药物制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310452983.1A Pending CN116492339A (zh) 2015-11-13 2016-05-10 一种组合物及其用途、药物制剂

Country Status (5)

Country Link
US (3) US20170135995A1 (https=)
JP (3) JP2019518738A (https=)
KR (1) KR102892545B1 (https=)
CN (2) CN106692973A (https=)
IL (2) IL300237A (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108042522A (zh) * 2017-12-29 2018-05-18 广东海洋大学 一种用于提高抗炎症功能的不饱和脂肪酸组合物及其应用
CN108159037A (zh) * 2017-12-29 2018-06-15 广东海洋大学 一种用于提高神经保护功能的不饱和脂肪酸组合物及其应用
WO2024245370A1 (zh) * 2023-05-31 2024-12-05 上海复宏汉霖生物技术股份有限公司 一种组合产品、盐及其用途

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102600891B1 (ko) * 2017-08-11 2023-11-13 센젠 하이타이드 바이오파마슈티컬 리미티드 염증성 장 질환의 치료를 위한 방법 및 조성물
ES2645028B2 (es) * 2017-10-13 2018-06-04 Maria D. GÓMEZ GARRE Preparación farmacéutica única y estable que contiene berberina, en formulación de liberación lenta, una estatina y ubiquinol para el tratamiento de la enfermedad cardiovascular y los factores de riesgo asociados
CN111499626A (zh) * 2019-01-31 2020-08-07 西南大学 一种表小檗碱的合成方法及应用
WO2026006683A1 (en) * 2024-06-28 2026-01-02 Wisteria Therapeutics, Inc. Omega-7 fatty acid berberine salt and methods of uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101879162A (zh) * 2010-02-23 2010-11-10 江苏格林生物科技有限公司 一种α-亚麻酸乙酯配伍小檗碱的减肥物
CN102580087A (zh) * 2012-03-08 2012-07-18 董萍 一种可用于人体局部减肥和美体的原位脂肪细胞系复合抑制剂及其制备方法
WO2015034984A1 (en) * 2013-09-05 2015-03-12 Emory University Nutritional formulas comprising medium chain fatty acids or esters thereof and methods related thereto

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1983989B1 (en) * 2006-02-09 2013-07-03 National Research Council of Canada Combinations of botanical extracts for promoting cardiovascular health
US20070196515A1 (en) * 2006-02-22 2007-08-23 Kothari Shil C Methods and compositions for improving cardiovascular risk factors and metabolic risk factors that cause syndrome X
US20080306154A1 (en) * 2006-11-03 2008-12-11 My Svensson Treatment and prevention of major adverse cardiovascular events or major coronary evens by administering Omega-3 fatty acids
WO2008134828A2 (en) * 2007-05-04 2008-11-13 Katholieke Universiteit Leuven Tissue degeneration protection
WO2009028457A1 (ja) * 2007-08-29 2009-03-05 Shinshu University 非アルコール性脂肪肝炎治療薬
WO2010104595A1 (en) * 2009-03-11 2010-09-16 Xintria Pharmaceutical Corporation, Inc. Methods and compositions for the treatment of metabolic and cardiovascular disorders
ES2530049T3 (es) * 2009-05-18 2015-02-26 Sigmoid Pharma Limited Composición que comprende gotas de aceite
CA2827561A1 (en) * 2011-02-16 2012-08-23 Pivotal Therapeutics, Inc. Omega 3 fatty acid diagniostic assay for the dietary management of patients with cardiovascular disease (cvd)
US9119826B2 (en) * 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
JP6359517B2 (ja) * 2012-03-30 2018-07-18 サンシリオ アンド カンパニー, インコーポレイテッドSancilio & Company, Inc. ω−３脂肪酸エステル組成物
US8652518B2 (en) * 2012-04-15 2014-02-18 Jahahreeh Finley Compositions and methods for the prevention and treatment of diseases or conditions associated with oxidative stress, inflammation, and metabolic dysregulation
CA2905671A1 (en) * 2013-03-13 2014-09-18 Matinas Biopharma Inc. Omega-3 pentaenoic acid compositions and methods of use
US20140322314A1 (en) * 2013-04-29 2014-10-30 Matinas Biopharma, Inc. Omega-3 Fatty Acid Formulations for Use as Pharmaceutical Treatment
IL282156B (en) * 2014-07-29 2022-07-01 Shenzhen Hightide Biopharmaceutical Ltd Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof
MA40846A (fr) * 2014-10-10 2017-09-05 Sancilio & Company Inc Compositions d'acides gras et d'esters d'acides gras auto-micellisantes, ainsi que leur utilisation dans le traitement d'états pathologiques
US9446100B2 (en) * 2015-02-13 2016-09-20 Eastern Vision Limited Dietary supplements and formulations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101879162A (zh) * 2010-02-23 2010-11-10 江苏格林生物科技有限公司 一种α-亚麻酸乙酯配伍小檗碱的减肥物
CN102580087A (zh) * 2012-03-08 2012-07-18 董萍 一种可用于人体局部减肥和美体的原位脂肪细胞系复合抑制剂及其制备方法
WO2015034984A1 (en) * 2013-09-05 2015-03-12 Emory University Nutritional formulas comprising medium chain fatty acids or esters thereof and methods related thereto

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108042522A (zh) * 2017-12-29 2018-05-18 广东海洋大学 一种用于提高抗炎症功能的不饱和脂肪酸组合物及其应用
CN108159037A (zh) * 2017-12-29 2018-06-15 广东海洋大学 一种用于提高神经保护功能的不饱和脂肪酸组合物及其应用
WO2024245370A1 (zh) * 2023-05-31 2024-12-05 上海复宏汉霖生物技术股份有限公司 一种组合产品、盐及其用途

Also Published As

Publication number Publication date
KR20230019269A (ko) 2023-02-08
US20170135995A1 (en) 2017-05-18
JP2022017496A (ja) 2022-01-25
IL300237A (en) 2023-03-01
IL262929B2 (en) 2023-07-01
US11369573B2 (en) 2022-06-28
US20200405646A1 (en) 2020-12-31
US11883539B2 (en) 2024-01-30
JP7448511B2 (ja) 2024-03-12
IL262929A (en) 2018-12-31
IL262929B1 (en) 2023-03-01
JP7668859B2 (ja) 2025-04-25
JP2019518738A (ja) 2019-07-04
JP2024014894A (ja) 2024-02-01
CN116492339A (zh) 2023-07-28
KR102892545B1 (ko) 2025-12-09
US20220296528A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
JP7668859B2 (ja) 組成物、ならびにその適用および薬学的調製の方法
US10988471B2 (en) Pharmaceutical composition comprising berberine ursodeoxycholic acid salt for the treatment of various diseases or disorders
AU2018381124A1 (en) Fatty acid derivatives for treating non-alcoholic steatohepatitis
CN108137575A (zh) 熊去氧胆酸与小檗碱或左旋肉碱的共轭化合物和其组合物及其方法
US20240139165A1 (en) Methods and compositions for treatment of inflammatory bowel disease
AU2023200123B2 (en) Composition, and application and pharmaceutical preparation thereof
WO2022137125A1 (en) Combination therapies comprising oxygen-containing structurally enhanced fatty acids for treatment of non-alcoholic steatohepatitis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20170524